AZN (AZN) Stock Price & Analysis
AZN (AZN) rose 0.59% to USD 169.26 as of July 25, 2026 at 01:44 UTC, according to Nexqual real-time market data.
AZN last closed at USD 168.27; the session ranged USD 168.33–170.26 on volume of 2,009,274 shares. Market capitalization is —, with a 52-week range of USD 142.98–212.71 (NYQ). Source: Nexqual, July 25, 2026 at 01:44 UTC.
Key Statistics (as of July 25, 2026 at 01:44 UTC)
| Price | USD 169.26 |
|---|---|
| Change | ▲ 0.59% (up) |
| Previous Close | USD 168.27 |
| Open | USD 169.84 |
| Day Range | USD 168.33 – 170.26 |
| 52-Week Range | USD 142.98 – 212.71 |
| Volume | 2,009,274 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (AZN)
Nexqual's technical model rates AZN "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 01:44 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.05 (neutral) |
| vs SMA50 | Below (USD 180.49) |
| MACD | -4.29 (negative) |
Analyst Ratings (AZN)
Wall Street analysts rate AZN "Buy" based on 10 analysts, with a mean price target of USD 213.89 (range USD 184–240), per Nexqual as of July 25, 2026 at 01:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 213.89 |
| High Target | USD 240 |
| Low Target | USD 184 |
| Buy / Hold / Sell | 8 / 2 / 0 |
Earnings (AZN)
| Next Earnings Date | 2026-07-27 |
|---|---|
| EPS Estimate | USD 1.27 |
| Revenue Estimate | $15.43B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.29 vs est 1.27 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
Financials & Fundamentals (AZN)
| Total Revenue | $60.44B |
|---|---|
| Revenue Growth (YoY) | +12.50% |
| Gross Margin | +81.50% |
| Operating Margin | +27.94% |
| Profit Margin | +17.19% |
| ROE | +23.48% |
| Debt / Equity | 71.82 |
| Current Ratio | 0.91 |
| Total Cash | $7.67B |
| Total Debt | $34.03B |
| Free Cash Flow | $6.56B |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
Financial Health Score (AZN)
Nexqual rates AZN's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:44 UTC.
| Growth | Solid — Revenue +13% YoY (latest Q) |
|---|---|
| Profitability | Strong — Gross margin 82%, operating 28% |
| Balance Sheet | Mixed — $7.67B cash vs $34.0B debt |
| Cash Flow | Solid — FCF $6.56B, 11% margin |
| Efficiency | Strong — ROE 23%, ROA 8.5% |
Ownership (AZN)
| Insider Ownership | +0.05% |
|---|---|
| Institutional Ownership | +68.36% |
| Float | 1.54B |
| Short % of Float | +0.10% |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
Leadership (AZN)
AZN is led by Pascal Claude Roland Soriot D.V.M. (age 66), CEO & Executive Director, per Nexqual as of July 25, 2026 at 01:44 UTC.
| CEO & Executive Director | Pascal Claude Roland Soriot D.V.M. (age 66) |
|---|---|
| CFO & Executive Director | Aradhana Sarin (age 51) |
| Executive Vice-President of BioPharmaceuticals Business Unit | Ruud Dobber |
| Executive Vice President of Oncology R & D | Susan Mary Galbraith (age 59) |
| Executive Vice President of International | Iskra Reic |
Major Backers & Investors (AZN)
Notable institutional backers of AZN include Investor AB, Capital International Investors, FMR, LLC, according to Nexqual as of July 25, 2026 at 01:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Investor AB | 3.33% |
| Capital International Investors | 2.22% |
| FMR, LLC | 1.91% |
| Capital Group | 1.82% |
| Wellington Management | 1.53% |
| Price (T.Rowe) Associates Inc | 1.26% |
| Bank of America Corporation | 1.23% |
| JPMorgan | 1.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.67% |
| Legal & General Group PLC | 1.67% |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GSK | GSK plc | USD 51.35 | ▲ 1.16% |
| NVS | Novartis AG | USD 155.01 | ▲ 1.26% |
| SNY | Sanofi | USD 43.35 | ▼ 1% |
| MRNA | Moderna, Inc. | USD 54.07 | ▼ 6.89% |
| BNTX | BioNTech SE | USD 89.33 | ▼ 2.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:44 UTC. This page is informational and not investment advice.